| Drug General Information |
| Drug ID |
D0S0QN
|
| Former ID |
DNC008722
|
| Drug Name |
2,5-bis(4-hydroxybenzylidene)cyclopentanone
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H16O3
|
| Canonical SMILES |
C1CC(=CC2=CC=C(C=C2)O)C(=O)C1=CC3=CC=C(C=C3)O
|
| InChI |
1S/C19H16O3/c20-17-7-1-13(2-8-17)11-15-5-6-16(19(15)22)12-14-3-9-18(21)10-4-14/h1-4,7-12,20-21H,5-6H2/b15-11+,16-12+
|
| InChIKey |
YSEMBYWAAKOCKW-JOBJLJCHSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cytochrome P450 3A4 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
|
Linoleic acid metabolism
|
|
Retinol metabolism
|
|
Metabolism of xenobiotics by cytochrome P450
|
|
Drug metabolism - cytochrome P450
|
|
Drug metabolism - other enzymes
|
|
Metabolic pathways
|
|
Bile secretion
|
|
Chemical carcinogenesis
|
|
PathWhiz Pathway
|
Caffeine Metabolism
|
|
Retinol Metabolism
|
|
Reactome
|
Xenobiotics
|
|
Aflatoxin activation and detoxification
|
|
WikiPathways
|
Metapathway biotransformation
|
|
Aflatoxin B1 metabolism
|
|
Estrogen metabolism
|
|
Benzo(a)pyrene metabolism
|
|
Tamoxifen metabolism
|
|
Tryptophan metabolism
|
|
Oxidation by Cytochrome P450
|
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Farnesoid X Receptor Pathway
|
|
Vitamin D Receptor Pathway
|
|
Felbamate Metabolism
|
|
Lidocaine metabolism
|
|
Nifedipine Activity
|
|
Colchicine Metabolic Pathway
|
|
Irinotecan Pathway
|
|
Drug Induction of Bile Acid Pathway
|
|
Fatty Acid Omega Oxidation
|
|
Codeine and Morphine Metabolism
|
| References |
| REF 1 | Eur J Med Chem. 2008 Aug;43(8):1621-31. Epub 2007 Nov 17.Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. |
|---|
